Ruxolitinib and oHSV Synergy: High-Dimensional Immune Profiling in Murine Sarcoma

Study Background and Research Question

Malignant peripheral nerve sheath tumors (MPNSTs) present a formidable clinical challenge due to their high aggressiveness, resistance to conventional therapies, and poor prognosis—especially for unresectable or metastatic disease. With limited FDA-approved treatment options, alternative strategies such as immunotherapies and virotherapies are under intense investigation. Oncolytic herpes simplex viruses (oHSVs) have shown promise by selectively lysing tumor cells and stimulating anti-tumor immunity. However, the complexity of the tumor immune microenvironment and the technical limitations in profiling rare or functionally diverse infiltrates have hampered comprehensive understanding of immune responses to such combinatorial therapies. The central research question of the reference study (Dhital et al., 2025) was whether combining the JAK1/JAK2 inhibitor Ruxolitinib (INCB018424) with oHSV virotherapy could more effectively modulate and characterize intratumoral immune compartments in murine sarcoma models.

Key Innovation from the Reference Study

The major advance reported by Dhital et al. is the development and application of a 46-parameter spectral flow cytometry panel, enabling unprecedented high-dimensional analysis of immune cell dynamics within the tumor microenvironment following repeated dosing with oHSV and Ruxolitinib. This approach overcomes the analytical bottleneck imposed by conventional flow cytometry, which is limited in both the number of detectable parameters and sensitivity when working with tumors containing low-abundance leukocyte infiltrates. The panel captures surface markers, intracellular cytokine expression, and transcription factors, facilitating simultaneous characterization of diverse immune subsets—including CD4/CD8 T cells, regulatory T cells (Tregs), B cell populations, natural killer T (NKT) cells, myeloid-derived suppressor cells (MDSCs), and dendritic cells. This technical advance is particularly relevant to myeloproliferative disorder research and oncogenic JAK2 fusion protein studies, where immune complexity underlies therapeutic outcomes.

Methods and Experimental Design Insights

The study utilized a genetically relevant murine model of MPNST, reflecting the disease spectrum seen in neurofibromatosis type 1 (NF1) patients. Mice were treated with Ruxolitinib (administered as a selective, ATP-competitive JAK1/2 inhibitor) in combination with oncolytic HSV. Tumor samples were harvested after repeated oHSV dosing, and immune cell populations were analyzed using the custom 46-color spectral flow cytometry panel. This panel was designed to resolve both lymphoid and myeloid compartments, and included intracellular staining for key cytokines (e.g., interferon-γ, interleukin-21, granzyme B) and transcription factors (e.g., FOXP3 for Tregs).

Spectral flow cytometry was selected over single-cell RNA sequencing or mass cytometry due to its accessibility, cost-effectiveness, and ability to deliver deep phenotyping even in samples with sparse immune infiltrates. The workflow also enabled detection of subtle but functionally important changes in cytokine-expressing T cell subsets and germinal center B cell activation—parameters often inaccessible via standard gating strategies.

Protocol Parameters

• Ruxolitinib dosing (murine model): Administered in vivo prior to and during oHSV therapy to achieve effective modulation of JAK-STAT signaling; dosing intervals and concentrations were tailored to match prior optimized protocols for immune modulation.
• oHSV administration: Repeated intratumoral injections to maintain oncolytic and immunostimulatory pressure on the tumor microenvironment.
• Spectral cytometry panel: 46-color panel incorporating surface, intracellular, and transcription factor markers to enable high-dimensional immune profiling in small tumor samples.
• Sample preparation: Tumors were digested into single-cell suspensions; viability dyes and Fc-block steps were included to optimize data quality.
• Control conditions: Monotherapy (Ruxolitinib or oHSV alone) and untreated controls were used to benchmark immune changes attributable to combination therapy.

Core Findings and Why They Matter

The combination of Ruxolitinib and oHSV produced several key immunological shifts within the tumor microenvironment, as detailed in the reference study:

• Enhanced CD4 T cell activation: There was a marked increase in cytokine-expressing CD4+ populations, including granzyme B+ cytotoxic-like, IFN-γ+ Th1-like, and IL-21+ T follicular helper (Tfh)-like phenotypes. These changes suggest a broadening of effector functions beyond cytotoxicity, potentially fostering anti-tumor immunity and supporting tertiary lymphoid structure formation within tumors.
• Expansion of germinal center B cell populations: The therapy promoted germinal center B cell activation and accumulation within the tumor, a feature associated with robust, adaptive anti-tumor responses and improved immunological memory.
• Comprehensive myeloid and lymphoid modulation: The high-dimensional panel revealed alterations not only in T cells but also in B cells, NKT cells, NK cells, monocytes, macrophages, granulocytes, MDSCs, and dendritic cells—demonstrating the broad immunomodulatory reach of the combined regimen.

These findings are significant because they highlight the potential of JAK-STAT signaling pathway inhibition, via agents like Ruxolitinib, to reshape the immune landscape of otherwise immune-cold tumors. By amplifying both innate and adaptive immune compartments, this strategy could overcome resistance mechanisms and improve outcomes in myeloproliferative and solid tumor settings.

Comparison with Existing Internal Articles

Several recent internal resources contextualize and extend the experimental advances highlighted in this study. For instance, "Translating JAK-STAT Inhibition: Mechanistic Insights and…" explores the versatility of Ruxolitinib (INCB018424) as a research tool in both myeloproliferative neoplasms and emerging immunotherapy combinations. That resource underscores the importance of high-dimensional immune profiling and advanced cytometry, aligning closely with the spectral flow approach adopted by Dhital et al. Similarly, "Ruxolitinib (INCB018424): Protocols and Innovations in JAK-STAT Research" provides laboratory protocols and troubleshooting guidance for researchers seeking to model JAK-STAT inhibition in sarcoma and hematologic malignancy contexts. The reference study’s innovation in spectral cytometry directly builds upon these established workflows by expanding the analytical resolution of immune cell dynamics. Finally, "Ruxolitinib (INCB018424) in Tumor Immunology: Workflows & Tips" highlights the reproducibility gains and combinatorial potential of APExBIO's research-grade formulation, further supporting the translational relevance of the present findings.

Limitations and Transferability

While the use of high-dimensional spectral flow cytometry represents a significant technical leap, certain limitations should be acknowledged. The findings are based on a murine sarcoma model, and while genetically relevant, there may be differences in immune landscape and therapy responsiveness in human tumors. The experimental design, while robust, still relies on preclinical endpoints, and the impact of these immune cell shifts on long-term tumor control and survival warrants further investigation. Additionally, although the spectral cytometry workflow is more accessible than mass cytometry or single-cell transcriptomics, it still requires specialized equipment and expertise, which may limit immediate adoption in some laboratories. Finally, the broader applicability of these immune shifts to other tumor types or to combination regimens with different oncolytic viruses remains an open question.

Research Support Resources

Researchers interested in recapitulating or extending these findings can leverage established protocols for JAK-STAT inhibition and immune profiling. For laboratory workflows requiring a potent, selective JAK1/2 inhibitor, Ruxolitinib (INCB018424) (SKU A3012) is widely used in both in vitro and in vivo applications, including myeloproliferative disorder research and oncogenic JAK2 fusion protein studies. Detailed product information—such as solubility, recommended storage, and dosing guidance—can support reproducibility and experimental design. For further protocol innovations and troubleshooting advice, the aforementioned internal articles provide practical insights for optimizing high-dimensional immune profiling in challenging tumor models.